Neobanks: Disruptive technology, elusive profits

For medtechs, overcoming the “valley of death” between FDA approval and coding, coverage, and payment for their innovations is a struggle. The proposed MCIT pathway could enable many start-ups to cross the valley more easily. Pricing remains a key unknown, but if the program is implemented, it could have far-reaching implications for innovators and their FDA Breakthrough devices. By David Lee…